Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
about
Bortezomib for the treatment of mantle cell lymphoma: an updateThe role of the ubiquitin proteasome system in cerebellar development and medulloblastomaCutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementProteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancerCrosstalk between apoptosis and autophagy: molecular mechanisms and therapeutic strategies in cancer.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and MethotrexateIKK inhibition increases bortezomib effectiveness in ovarian cancer.Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.Bortezomib for the treatment of non-Hodgkin's lymphomaRegulation and function of nuclear IκBα in inflammation and cancerRadiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen speciesProteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cellsTargeted molecular therapy in peripheral T-cell lymphomas.Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.NFκB function and regulation in cutaneous T-cell lymphoma.From empiric to mechanism-based therapy for peripheral T cell lymphoma.Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myelomaBortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.Synergistic inhibition of PARP-1 and NF-κB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy.T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy.The 1,4 benzoquinone-featured 5-lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells.Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells.Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma.DMF: a promising therapeutic option in CTCL.ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.Association of growth factors, HIF-1 and NF-κB expression with proteasomes in endometrial cancer.The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities.Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice.Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL-1β production.TAFRO syndrome: current perspectives.Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma.
P2860
Q26738940-91F1AB9C-04D2-41D2-AB3B-F485235B5BA9Q26782159-7637A5EA-E8A0-4506-A3E0-4E920BCDFA0AQ27024076-D7DDEABA-C4F4-465F-A3A2-77FA59A8FF1EQ27307731-09006AB4-4C95-4AD0-BCB0-FB403F63DFB4Q34102626-2EC8EE59-60C6-4BBB-A058-CF5BAC9F8AA0Q35022833-5F39210F-AB1A-415D-9444-35BC98D9A56CQ36255777-C67DDDAC-D9C0-4EF4-967E-372AAA57D5FCQ36413454-B509E68E-BC87-4936-8E49-28DA55CE1198Q36470196-50C453F5-3036-4B44-9035-8E9A03FEE3C2Q36815262-D4B0A919-091E-46FB-81F0-CC85E95245B0Q36868056-2DD3FCEE-AB53-43B9-8A35-9BC3A7C96D6AQ37021647-178C1CA3-B9B0-40AB-A586-56535124EEAEQ37309407-6E721EFB-C286-4503-8F54-7CEF6922A9DBQ37536497-0CC9EF39-D3AB-44FA-869A-23F8D5A82787Q37706483-126451D8-EA73-4921-9D7B-8AC449CDB398Q37937044-2DC06AD6-58E0-4158-89DE-7ABDCEC1F3B5Q37944565-44922FF8-2018-4460-BDD1-DA3D86B556BEQ37998019-2FFD2200-0F54-40D9-B1E2-74C0ADB8A3E4Q38162229-F0E57EAC-70FD-4A00-ACF4-B78968CB5D36Q38186617-6F2B44AE-A029-4EEB-9F85-D6A2AF2651BBQ38294626-99425AAC-300B-467B-92B2-153B8771CBFAQ38855013-266B6DB9-6562-41A2-B9B5-1ACAD7F86165Q38878577-92C39C49-DFAC-41E8-AE70-1216E0BBAB09Q38909786-A82C24BA-731D-4AD5-B363-34C9BE5F380EQ39119033-0B5A1A9F-667E-4EB2-9F1A-E7A9F9916768Q39187805-E5FA3C4B-49D3-4643-9B40-C35C92528AACQ40458807-CC9593DA-EC5E-4FCE-87F0-652DCB2497B5Q40476069-A67912AB-A2A7-4B8E-A6CD-2DF27B4E0B71Q41539725-B820D4C5-B0BD-422A-B401-B8E942C9EC08Q41543982-366DE343-47C4-419C-A7CD-7F4829EEB5E0Q42004035-ABA25142-9B3A-462C-AE92-2538944CC838Q42361264-8ABE29F8-6495-48E2-8602-DCC8659D5D98Q42365296-8C1AE182-830B-409E-9FD6-711010260C33Q47605422-E9B07F3D-B27A-4D7E-8961-9D9A60886DD4Q48000346-238E32FD-DBD8-4E17-98C3-4EA8A504AC8DQ48034709-CAABCFDC-33BF-48D5-A157-760E335449D0Q48098911-5762FBCF-BE28-4F21-9143-A173495E3375Q48507691-EC5FBB18-9B32-4DC1-88BF-FD42CB43BD56Q49384282-45B2EE86-3726-4778-AD8E-6DFF084958CDQ55022904-97B1E71C-3F22-4375-BA86-9009328EB1E3
P2860
Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bortezomib induces nuclear tra ...... nduction of apoptosis in CTCL.
@ast
Bortezomib induces nuclear tra ...... nduction of apoptosis in CTCL.
@en
Bortezomib induces nuclear tra ...... nduction of apoptosis in CTCL.
@nl
type
label
Bortezomib induces nuclear tra ...... nduction of apoptosis in CTCL.
@ast
Bortezomib induces nuclear tra ...... nduction of apoptosis in CTCL.
@en
Bortezomib induces nuclear tra ...... nduction of apoptosis in CTCL.
@nl
prefLabel
Bortezomib induces nuclear tra ...... nduction of apoptosis in CTCL.
@ast
Bortezomib induces nuclear tra ...... nduction of apoptosis in CTCL.
@en
Bortezomib induces nuclear tra ...... nduction of apoptosis in CTCL.
@nl
P2093
P2860
P1476
Bortezomib induces nuclear tra ...... nduction of apoptosis in CTCL.
@en
P2093
Ashish Juvekar
Chandra C Ghosh
Hai-Yen Vu
Ivana Vancurova
Mahmut Y Celiker
Sitharam Ramaswami
Subrata Manna
Tzu-Pei Chang
P2860
P304
P356
10.1158/1541-7786.MCR-10-0368
P577
2011-01-11T00:00:00Z